Bleeding risk assessment for venous thromboembolism prophylaxis.
Maria Chiara Chindamo, Marcos Arêas Marques
https://pubmed.ncbi.nlm.nih.gov/34093680/Actively Recruiting
Led by Science Valley Research Institute · Updated on 2025-03-12
100
Participants Needed
1
Research Sites
1 weeks
Total Duration
Researchers are evaluating the incidence of venous thromboembolism VTE in patients with multiple health conditions undergoing complex lower limb revascularization surgeries. The study focuses on comparing the use of rivaroxaban combined with aspirin against single antiplatelet treatments for preventing VTE. This trial addresses the lack of consensus on using direct oral anticoagulants for extended VTE prevention in such patients. Participants will be randomly assigned to one of two groups one receiving rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily, and the other receiving standard single antiplatelet therapy clopidogrel followed by aspirin or aspirin alone depending on the procedure. Treatment will continue for three months, with visits every two weeks and a mandatory Doppler ultrasound at day 30 to assess outcomes. During the study, patients will keep a symptom diary and attend regular clinic visits for tests and checkups. Researchers will measure the occurrence of VTE and monitor safety outcomes at 30 days after surgery. The trial includes 200 participants undergoing either endovascular or open surgery, with ongoing monitoring to evaluate the effectiveness and safety of the treatments over the study period.
CONDITIONS
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
G
Gabriela Oliveira Buril, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Science Valley Research Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 30 days
Participants take either rivaroxaban 2.5 mg twice daily plus aspirin 100 mg or a single antiplatelet agent following lower limb revascularization surgery.
Biweekly visits for checkups and tests, with a mandatory Doppler ultrasound at day 30
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maria Chiara Chindamo, Marcos Arêas Marques
https://pubmed.ncbi.nlm.nih.gov/34093680/Nabil N Dagher, J Gregory Modrall
https://pubmed.ncbi.nlm.nih.gov/17386359/Marc P Bonaca, Rupert M Bauersachs, Sonia S Anand...
https://pubmed.ncbi.nlm.nih.gov/32222135/Michael K Gould, David A Garcia, Sherry M Wren...
https://pubmed.ncbi.nlm.nih.gov/22315263/Tarek Haykal, Yazan Zayed, Josiane Kerbage...
https://pubmed.ncbi.nlm.nih.gov/34508872/Gabriela de Oliveira Buril, Maria Fernanda Portugal, Samantha Neves...
https://pubmed.ncbi.nlm.nih.gov/41232756/Science Valley Research Institute
Lead Sponsor